

# Content of N2 Bulletin, 2016

## + REGULATORY NEWS

- **CMDH ENDORSES REVOCATION OF AUTHORISATIONS FOR FUSAFUNGINE SPRAYS USED TO TREAT AIRWAY INFECTIONS**

## + DRUGS SAFETY

- **FDA TO REVIEW STUDY EXAMINING USE OF ORAL FLUCONAZOLE (DIFLUCAN) IN PREGNANCY**
- **ATYPICAL NEUROLEPTICS IN ELDERLY PATIENTS: ACUTE KIDNEY INJURY**
- **DRUG-INDUCED URINARY INCONTINENCE**

## + THE INTERESTING FACTS

- **NEW TREATMENT FOR COMMON INCURABLE EYE CONDITION**
- **PATCH DELIVERS INSULIN BETA CELLS TO CONTROL DIABETES**

## + EVIDENCE BASED MEDICINES

- **OSELTAMIVIR AND INFLUENZA: STILL NO ROBUST DATA**
- **OSELTAMIVIR FOR INFLUENZA, FROM BIRTH: NO MORE USEFUL THAN IN ADULTS**  
No evaluation in infants less than 1 year old
- **PASIREOTIDE IN ACROMEGALY**  
After treatment failure: better than pegvisomant
- **VEMURAFENIB WITH LONGER FOLLOW-UP**  
Metastatic melanoma: a few extra months of life, but many adverse effects

## + PRACTICAL RECOMMENDATIONS

- **THE ETHICS OF TREATING COUGH IN THE LITTLEST KIDS**
- **HELICOBACTER PYLORI AND GASTRIC OR DUODENAL ULCER**  
First-line empirical treatment in 2015: amoxicillin + clarithromycin + metronidazole
- **RITUXIMAB AND SEVERE POLYANGIITIS**  
An option for patients informed of the uncertainties